Zhou You-xin, Huang Yu-lun
Department of Neurosurgery, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Chin Med J (Engl). 2009 Jul 20;122(14):1666-73.
Celastrol is a major active component of Tripterygium wilfordii named "Thunder God Vine", which is widely used to treat rheumatoid arthritis in China. The present study aims to demonstrate that celastrol has potent anticancer activity against glioma in vitro and in vivo.
Proliferation, migration, and tube formation of ECV-304 cells were determined by MTT and matrigel assays. The antiangiogenesis effect of celastrol was assessed by the chick chorioallantoic membrane assay and the in vivo matrigel plug assay. Tumor microvessels (MVD) were determined immunohistochemically with anti-CD34 antibody. Vascular endothelial growth factor (VEGF) expression was defined as positive if distinct staining of the cytoplasm was observed in at least 10% of tumor cells at the deepest invasive site, central portion and superficial part of the tumor. MVD was estimated by averaging the counts of three times at a x 200 field in the most vascularized area of the deepest invasive site.
Celastrol purified from T. wilfordii inhibited the proliferation of vascular endothelial cells (ECV-304) with an IC50 value of 1.33 microg/ml. Celastrol, at the concentration of 0.2 microg/ml, significantly inhibited cell migration and tube formation. Celastrol inhibited angiogenesis in a dose-dependent manner both in vitro and in vivo. Subcutaneous administration of celastrol 5 days a week for 4 consecutive weeks significantly reduced tumor volume in a dose-dependent manner in the SHG-44 xenograft model. Celastrol at each different dose level lowered the density of MVD significantly in tumor bearing nude mice compared to the control group. Immunohistochemistry experiments further revealed that celastrol also decreased the level of VEGFR-1 and VEGFR-2 expression, but not the level of VEGF expression.
Celastrol elicits antiangiogenic effects in vitro and in vivo, and could be of potential use in the treatment of malignant cancers such as glioblastoma.
雷公藤红素是名为“雷公藤”的雷公藤的主要活性成分,在中国广泛用于治疗类风湿性关节炎。本研究旨在证明雷公藤红素在体外和体内对胶质瘤具有强大的抗癌活性。
通过MTT和基质胶试验测定ECV - 304细胞的增殖、迁移和管形成。通过鸡胚绒毛尿囊膜试验和体内基质胶栓试验评估雷公藤红素的抗血管生成作用。用抗CD34抗体通过免疫组织化学法测定肿瘤微血管(MVD)。如果在肿瘤最深浸润部位、中央部分和浅表部分至少10%的肿瘤细胞中观察到细胞质有明显染色,则血管内皮生长因子(VEGF)表达定义为阳性。在最深浸润部位血管最丰富区域的x200视野下,通过对三次计数求平均值来估计MVD。
从雷公藤中纯化得到的雷公藤红素抑制血管内皮细胞(ECV - 304)的增殖,IC50值为1.33微克/毫升。浓度为0.2微克/毫升的雷公藤红素显著抑制细胞迁移和管形成。雷公藤红素在体外和体内均以剂量依赖性方式抑制血管生成。在SHG - 44异种移植模型中,每周皮下注射雷公藤红素5天,连续4周,以剂量依赖性方式显著降低肿瘤体积。与对照组相比,每个不同剂量水平的雷公藤红素均显著降低荷瘤裸鼠的MVD密度。免疫组织化学实验进一步表明,雷公藤红素还降低了VEGFR - 1和VEGFR - 2的表达水平,但未降低VEGF的表达水平。
雷公藤红素在体外和体内均具有抗血管生成作用,可能在治疗恶性肿瘤如胶质母细胞瘤方面具有潜在用途。